Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 638-747-5 | CAS number: 1228186-17-1
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Repeated dose toxicity: oral
Administrative data
- Endpoint:
- sub-chronic toxicity: oral
- Type of information:
- migrated information: read-across from supporting substance (structural analogue or surrogate)
- Adequacy of study:
- supporting study
- Study period:
- From 2002-10-11 to 2003-12-02
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: GLP guideline study
Cross-reference
- Reason / purpose for cross-reference:
- read-across source
Reference
- Endpoint:
- sub-chronic toxicity: oral
- Type of information:
- read-across from supporting substance (structural analogue or surrogate)
- Adequacy of study:
- supporting study
- Reason / purpose for cross-reference:
- read-across source
- Reason / purpose for cross-reference:
- assessment report
- Sex:
- female
- Route of administration:
- oral: gavage
- Clinical signs:
- effects observed, treatment-related
- Description (incidence and severity):
- no mortality throughout study period
- Mortality:
- mortality observed, treatment-related
- Description (incidence):
- no mortality throughout study period
- Body weight and weight changes:
- effects observed, treatment-related
- Description (incidence and severity):
- mid and high dose
- Food consumption and compound intake (if feeding study):
- effects observed, treatment-related
- Description (incidence and severity):
- mid and high dose
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- no effects observed
- Haematological findings:
- effects observed, treatment-related
- Description (incidence and severity):
- high dose
- Clinical biochemistry findings:
- effects observed, treatment-related
- Description (incidence and severity):
- mid and high dose
- Urinalysis findings:
- not examined
- Behaviour (functional findings):
- no effects observed
- Organ weight findings including organ / body weight ratios:
- effects observed, treatment-related
- Description (incidence and severity):
- high dose
- Gross pathological findings:
- effects observed, treatment-related
- Description (incidence and severity):
- mid and high dose
- Histopathological findings: non-neoplastic:
- effects observed, treatment-related
- Description (incidence and severity):
- mid and high dose
- Histopathological findings: neoplastic:
- not examined
- Details on results:
- CLINICAL SIGNS AND MORTALITY:
General clinical signs: 6000 ppm: Emaciated appearance in 1/10 male and 2/10 female; Soft feces in 1/10 males and 8/10 females. Further in females: Area of hair loss or scattered hair (6/10) and one female showed a round back. Although 1/10 males given 1500 ppm showed piloerection, no noteworthy clinical signs were observed in any other group over the considered period.
Detailed clinical signs - Except soft feces noted in females at 6000 ppm, the detailed clinical observation had shown no perturbation of the autonomic or physiological functions in any treated group.
- No mortality occurred during the study period.
BODY WEIGHT AND WEIGHT GAIN: Decreased food consumption and body weight gain which were noted in treated males and females at 1500 ppm during the first week of the study, were considered to be related to palatability of the compound in the diet, resulting in a lower food consumption and lower body weight gain. The body weight gain and food consumption of treated animals at 3000 and 6000 ppm was affected by the oral administration (dietary admixture) of DDAC.
FOOD CONSUMPTION AND COMPOUND INTAKE (if feeding study): When compared to controls, food consumption of animals treated at 3000 and 6000 ppm was affected during the whole treatment period, with a more marked effect at the highest concentration.
Also in the 1500 ppm group the food intake is decreased during the first treatment week.
OPHTHALMOSCOPIC EXAMINATION: No relevant ophthalmological findings were observed in any group.
HAEMATOLOGY: When compared with control values, a decrease in WBC count was recorded in all treated males and females treated at 6000 ppm. A tendency for lower WBC was observed in treated females at 3000 ppm.
CLINICAL CHEMISTRY: - increase in sodium, chloride and inorganic phosphorus plasma levels at 6000 ppm,
- a tendency for decrease in glucose levels in treated groups at 6000 ppm and in females treated at 3000 ppm,
- increase in urea and creatinine plasma levels in all treated male groups, and only a tendency for higher urea values in females treated at 6000 ppm,
- decrease in protein concentration in the 6000 ppm group,
- increase in A/G ratio in males treated at 3000 and 6000 ppm and in females treated at 6000 ppm. This difference could be explained by a decrease in globulins in males. In females, decrease in albumin was noted at 6000 ppm,
- dose-related decreased triglyceride in treated males, a tendency for lower cholesterol values in treated females at 6000 ppm,
- increase in transaminase activities in females treated at 6000 ppm.
ORGAN WEIGHTS: Relative and absolute organ weight differences to control are mostly related to low body weights in 6000 ppm group. Absolute kidney weights are also depressed in mid-dose groups.
GROSS AND HISTOPATHOLOGY: Distended coecum with feces in 9/10 males and all females of the high dose group, and in 4/10 males and 3/10 females of the mid-dose group. Similarly distended colon with faeces was observed in 4/10 males and 2/10 females of the high-dose group.
A brownish colour of the mesenteric lymphnodes was seen in 2/10 males and 4/10 females of the high-dose group, and in one male of the mid-dose group. Histiocytosis and mastocytosis in the mesenteric lymph node were seen at histopathology at and above 3000 ppm.
OTHER FINDINGS
Functional Observation Battery (FOB) - There were no perturbation of either autonomic or physiological functions at any dose-levels. - Dose descriptor:
- NOAEL
- Effect level:
- 1 500 ppm
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: Body weight; food consumption; gross pathology; histopathology
- Dose descriptor:
- LOAEL
- Effect level:
- 3 000 ppm
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: Body weight; food consumption; gross pathology; histopathology
- Critical effects observed:
- not specified
- Conclusions:
- The NOAEL of the test material was determined to be 1500 ppm (corresponding to 61.5 mg test item/kg/d for the males and 71.7 mg test item/kg/d for the females).
Under the test conditions, the NOAEL of the test material was determined to be 1500 ppm(corresponding to 42 mg DDAC/kg/d for the males and 49 mg DDAC/kg/d for the females) in rats - Executive summary:
The study used as source investigated repeated oral toxicity. The study results of the source compound were considered applicable to the target compound. Justification and applicability of the read-across approach (structural analogue) is outlined in the read-across report in section 13 or find a link in cross reference “assessment report”.
At 6000 ppm, main treatment-related findings were: soft feces, body weight loss (week 1), lower body weight gain and food consumption, perturbation of hematological and blood biochemical parameters, distension of the cecum/colon with feces in all animals, histiocytosis, mastocytosis and sinusal hemorrhage in the mesenteric lymph node, consistent with a continued action of a mild irritant. At 3000 ppm, body weight gain and food consumption were affected, changes at clinical pathology were noted, the cecum was distended with feces in about third of the animals, histiocytosis and mastocytosis in the mesenteric lymph node were seen at histopathology. At 1500 ppm, minor changes in hematological and blood biochemical parameters were recorded which were not considered to be of toxicological relevance. The most obvious effect is the lowering of the food intake caused by the palatability of the compound, which at lower levels improves after some time. Some effects seen in haematology and blood chemistry at the higher dose levels could very well result from a poor alimentary status as opposed to a specific toxic mechanism. At the highest dose level, the finding of distended cecum and/or colon becomes noteworthy, and possibly a higher severity of histiocytosis at microscopic examination, although this aspect is also already observed in controls.
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 004
- Report date:
- 2004
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 408 (Repeated Dose 90-Day Oral Toxicity Study in Rodents)
- GLP compliance:
- yes (incl. QA statement)
- Limit test:
- no
Test material
- Reference substance name:
- Didecyldimethylammonium chloride
- EC Number:
- 230-525-2
- EC Name:
- Didecyldimethylammonium chloride
- Cas Number:
- 7173-51-5
- Molecular formula:
- C22H48N.Cl
- IUPAC Name:
- N-decyl-N,N-dimethyldecan-1-aminium chloride
- Details on test material:
- - Name of test material (as cited in study report): Arquad 2.10-40
- Composition of test material, percentage of components: ca. 40% Didecyldimethylammonium chloride (CAS no.: 7173-51-5) in water only.
- Batch No.: FP019980246
- Physical state: Colourless to pale yellowish liquid
- Analytical purity: 42.9% active ingredient in water
- Stability: Stable
Constituent 1
Test animals
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Cesarian Obtained, Barrier Sustained-Virus Antibody Free (COBS-VAF®).
- Age at study initiation: 6 wk at Day 1 of treatment
- Weight at study initiation: Males: 185 g; females: 153 g
Administration / exposure
- Route of administration:
- oral: feed
- Vehicle:
- unchanged (no vehicle)
- Details on oral exposure:
- - Type: Oral via diet in feed
- Vehicle: Plain diet - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- No data
- Duration of treatment / exposure:
- 93 days
- Frequency of treatment:
- Daily
Doses / concentrations
- Remarks:
- Doses / Concentrations:
0, 1500, 3000 and 6000 ppm of test material in diet corresponds to active substance DDAC (males/females): 1500 ppm: 42 mg/kg/d /49 mg/kg/d; 3000 ppm : 84 / 96 mg/kg/d; 6000 ppm : 175 / 201 mg/kg/d (males / females respectively)
Basis:
actual ingested
- No. of animals per sex per dose:
- 10 animals/sex/dose
- Control animals:
- yes, plain diet
- Details on study design:
- None
- Positive control:
- None
Examinations
- Observations and examinations performed and frequency:
- CAGE SIDE OBSERVATIONS: Yes
DETAILED CLINICAL OBSERVATIONS: Yes
BODY WEIGHT: Yes
- Time schedule for examinations: Once a wk
FOOD CONSUMPTION AND COMPOUND INTAKE (if feeding study): Yes
- Food consumption for each animal determined and mean daily diet consumption calculated as g food/kg body weight/day: Yes
OPHTHALMOSCOPIC EXAMINATION: Yes
- Time schedule for examinations: at beginning and end of study
HAEMATOLOGY: Yes
- Number of animals: all animals
- Time points: end of study
- Parameters: Haematocrit, haemoglobin concentration, erythrocyte count, total and differential leukocyte count, platelet count, prothrombin time
CLINICAL CHEMISTRY: Yes
- Number of animals: all animals
- Time points: end of study
- Parameters: sodium, potassium, chloride, calcium, Inorg. Phosphorous, glucose, urea, total bilirubin, creatinine, total protein, albumin, total cholesterol, alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, lipids.
URINALYSIS: No - Sacrifice and pathology:
- -Organ weights: Yes, all animals
-Organs: adrenals, liver, kidneys, adrenals, testes, epididymides, uterus, ovaries, thymus, thyroid, spleen, brain, heart
-Gross and histopathology: Yes, all animals of control and high dose group, animals that prematurely died, and all macroscopic lesions.
Animals of intermediate dose group also investigated in full when possible effects are seen in highest dose group.
-Organs: Macroscopic lesions, Adrenals, Aorta, Brain (including medulla/pons, cerebellar and cerebral cortex), Cecum, Colon, Duodenum, Epididymides, Esophagus, Eyes with Harderian glands, Femoral bone with articulation, Heart, Ileum, Jejunum, Kidneys, Liver, Lungs with bronchi, Lymph nodes
(mandibular and mesenteric), Mammary glands/area, Ovaries (with oviducts), Pancreas, Pituitary gland, Prostate (dorso-lateral and ventral),
Rectum, Salivary glands (sublingual and submandibular), Sciatic nerve, Seminal vesicles (including coagulation gland), Skeletal muscle, Skin,
Spinal cord (cervical, thoracic and lumbar), Spleen, Sternum with bone marrow, Stomach with forestomach, Testes, Thymus, Thyroids with
parathyroids, Tongue, Trachea, Urinary bladder, Uterus (horns and cervix), Vagina.
Additionally, mesenteric lymph nodes of the low- and intermediate-dose groups were examined. - Other examinations:
- -Other examinations: Functional observation battery (FOB)
- Statistics:
- Depending on normal distribution (Kolmogorov–Lilliefors test, possibly after a Logarithmic transformation of the values – except
for organ weights) and following testing of homogeneity of variances between groups: Bartlett test (3 or more groups) or Fisher test (2 groups).
If Homogeneous: Student test (2 groups) or Dunnett test (3 or more groups),
Else: Dunn test (3 or more groups) or Mann–Whitney/Wilcoxon test (2 groups)
If not normal distribution: Dunn test
Results and discussion
Results of examinations
- Clinical signs:
- effects observed, treatment-related
- Description (incidence and severity):
- no mortality throughout study period
- Mortality:
- mortality observed, treatment-related
- Description (incidence):
- no mortality throughout study period
- Body weight and weight changes:
- effects observed, treatment-related
- Description (incidence and severity):
- mid and high dose
- Food consumption and compound intake (if feeding study):
- effects observed, treatment-related
- Description (incidence and severity):
- mid and high dose
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- no effects observed
- Haematological findings:
- effects observed, treatment-related
- Description (incidence and severity):
- high dose
- Clinical biochemistry findings:
- effects observed, treatment-related
- Description (incidence and severity):
- mid and high dose
- Urinalysis findings:
- not examined
- Behaviour (functional findings):
- no effects observed
- Organ weight findings including organ / body weight ratios:
- effects observed, treatment-related
- Description (incidence and severity):
- high dose
- Gross pathological findings:
- effects observed, treatment-related
- Description (incidence and severity):
- mid and high dose
- Histopathological findings: non-neoplastic:
- effects observed, treatment-related
- Description (incidence and severity):
- mid and high dose
- Histopathological findings: neoplastic:
- not examined
- Details on results:
- CLINICAL SIGNS AND MORTALITY:
General clinical signs: 6000 ppm: Emaciated appearance in 1/10 male and 2/10 female; Soft feces in 1/10 males and 8/10 females. Further in females: Area of hair loss or scattered hair (6/10) and one female showed a round back. Although 1/10 males given 1500 ppm showed piloerection, no noteworthy clinical signs were observed in any other group over the considered period.
Detailed clinical signs - Except soft feces noted in females at 6000 ppm, the detailed clinical observation had shown no perturbation of the autonomic or physiological functions in any treated group.
- No mortality occurred during the study period.
BODY WEIGHT AND WEIGHT GAIN: Decreased food consumption and body weight gain which were noted in treated males and females at 1500 ppm during the first week of the study, were considered to be related to palatability of the compound in the diet, resulting in a lower food consumption and lower body weight gain. The body weight gain and food consumption of treated animals at 3000 and 6000 ppm was affected by the oral administration (dietary admixture) of DDAC.
FOOD CONSUMPTION AND COMPOUND INTAKE (if feeding study): When compared to controls, food consumption of animals treated at 3000 and 6000 ppm was affected during the whole treatment period, with a more marked effect at the highest concentration.
Also in the 1500 ppm group the food intake is decreased during the first treatment week.
OPHTHALMOSCOPIC EXAMINATION: No relevant ophthalmological findings were observed in any group.
HAEMATOLOGY: When compared with control values, a decrease in WBC count was recorded in all treated males and females treated at 6000 ppm. A tendency for lower WBC was observed in treated females at 3000 ppm.
CLINICAL CHEMISTRY: - increase in sodium, chloride and inorganic phosphorus plasma levels at 6000 ppm,
- a tendency for decrease in glucose levels in treated groups at 6000 ppm and in females treated at 3000 ppm,
- increase in urea and creatinine plasma levels in all treated male groups, and only a tendency for higher urea values in females treated at 6000 ppm,
- decrease in protein concentration in the 6000 ppm group,
- increase in A/G ratio in males treated at 3000 and 6000 ppm and in females treated at 6000 ppm. This difference could be explained by a decrease in globulins in males. In females, decrease in albumin was noted at 6000 ppm,
- dose-related decreased triglyceride in treated males, a tendency for lower cholesterol values in treated females at 6000 ppm,
- increase in transaminase activities in females treated at 6000 ppm.
ORGAN WEIGHTS: Relative and absolute organ weight differences to control are mostly related to low body weights in 6000 ppm group. Absolute kidney weights are also depressed in mid-dose groups.
GROSS AND HISTOPATHOLOGY: Distended coecum with feces in 9/10 males and all females of the high dose group, and in 4/10 males and 3/10 females of the mid-dose group. Similarly distended colon with faeces was observed in 4/10 males and 2/10 females of the high-dose group.
A brownish colour of the mesenteric lymphnodes was seen in 2/10 males and 4/10 females of the high-dose group, and in one male of the mid-dose group. Histiocytosis and mastocytosis in the mesenteric lymph node were seen at histopathology at and above 3000 ppm.
OTHER FINDINGS
Functional Observation Battery (FOB) - There were no perturbation of either autonomic or physiological functions at any dose-levels.
Effect levels
open allclose all
- Dose descriptor:
- NOAEL
- Effect level:
- 1 500 ppm
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: Body weight; food consumption; gross pathology; histopathology
- Dose descriptor:
- LOAEL
- Effect level:
- 3 000 ppm
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: Body weight; food consumption; gross pathology; histopathology
Target system / organ toxicity
- Critical effects observed:
- not specified
Any other information on results incl. tables
At 6000 ppm, main treatment-related findings were: soft feces, body weight loss (week 1), lower body weight gain and food consumption, perturbation of hematological and blood biochemical parameters, distension of the cecum/colon with feces in all animals, histiocytosis, mastocytosis and sinusal hemorrhage in the mesenteric lymph node, consistent with a continued action of a mild irritant. At 3000 ppm, body weight gain and food consumption were affected, changes at clinical pathology were noted, the cecum was distended with feces in about third of the animals, histiocytosis and mastocytosis in the mesenteric lymph node were seen at histopathology. At 1500 ppm, minor changes in hematological and blood biochemical parameters were recorded which were not considered to be of toxicological relevance. The most obvious effect is the lowering of the food intake caused by the palatability of the compound, which at lower levels improves after some time. Some effects seen in haematology and blood chemistry at the higher dose levels could very well result from a poor alimentary status as opposed to a specific toxic mechanism. At the highest dose level, the finding of distended cecum and/or colon becomes noteworthy, and possibly a higher severity of histiocytosis at microscopic examination, although this aspect is also already observed in controls.
Applicant's summary and conclusion
- Conclusions:
- The NOAEL of the test material was determined to be 1500 ppm (corresponding to 42 mg DDAC/kg/d for the males and 49 mg DDAC/kg/d for the females).
Under the test conditions, the NOAEL of the test material was determined to be 1500 ppm(corresponding to 42 mg DDAC/kg/d for the males and 49 mg DDAC/kg/d for the females) in rats - Executive summary:
The potential systemic toxicity of the test material (40% didecyldimethylammonium chloride in water) was evaluated following repeated oral administration to rats according to OECD Guideline 408. The study was conducted in compliance with the principles of Good Laboratory Practice regulations. The test material was given by dietary admixture to Sprague-Dawley rats for 13 weeks at the concentration of 1500, 3000 or 6000 ppm (corresponding to 42, 84 or 175 mg of DDAC/kg bw/day for the males and 49, 96 or 201 mg of DDAC/kg bw/day for the females). All animals were monitored for toxic effects including clinical observations, body and organ weights, hematology, serum chemistry, macroscopic and microscopic evaluations. At 6000 ppm, main treatment-related findings were: soft feces, body weight loss (at week 1), lower body weight gain and food consumption, perturbation of hematological and blood biochemical parameters, distension of the cecum/colon with feces in all animals, histiocytosis, mastocytosis and sinusal hemorrhage in the mesenteric lymph node, consistent with a continued action of an irritant. At 3000 ppm, body weight gain and food consumption were affected, changes at clinical pathology were noted, the cecum was distended with feces in about third of the animals, histiocytosis and mastocytosis in the mesenteric lymph node were seen at histopathology. At 1500 ppm, minor changes in hematological and blood biochemical parameters were recorded which were not considered to be of biological significance and therefore considered of no toxicological relevance. Based on these findings it was concluded that the NOAEL of didecyldimethylammonium chloride following repeated dietary administration of 90 days was 1500 ppm which corresponds to 42 mg DDAC/kg bw /day for the males and 49 mg DDAC/kg bw/day for the females. The overall NOAEL for both males and females is set at 46 mg/kg bw/day.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.